|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on September 12, 2002; DOI 10.1182/blood-2002-07-2009.
REVIEW ARTICLE
From the Lymphoma Group, Molecular Pathology Program,
Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid,
Spain.
Disruption of the physiologic balance between cell proliferation
and death is a universal feature of all cancers. In general terms,
human B-cell lymphomas can be subdivided into 2 main groups, low- and
high-growth fraction lymphomas, according to the mechanisms through
which this imbalance is achieved. Most types of low-growth fraction
lymphomas are initiated by molecular events resulting in the inhibition
of apoptosis, such as translocations affecting BCL2, in
follicular lymphoma, or BCL10 and API2/MLT1, in
mucosa-associated lymphoid tissue (MALT) lymphomas. This
results in cell accumulation as a consequence of prolonged cell
survival. In contrast, high-growth fraction lymphomas are characterized
by an enhanced proliferative activity, as a result of the deregulation
of oncogenes with cell cycle regulatory functions, such as
BCL6, in large B-cell lymphoma, or c-myc, in
Burkitt lymphoma. Low- and high-growth fraction lymphomas are both able
to accumulate other alterations in cell cycle regulation, most
frequently involving tumor suppressor genes such as
p16INK4a, p53, and
p27KIP1. As a consequence, these tumors behave
as highly aggressive lymphomas. The simultaneous inactivation of
several of these regulators confers increased aggressivity and
proliferative advantage to tumoral cells. In this review we discuss our
current knowledge of the alterations in each of these pathways, with
special emphasis on the deregulation of cell cycle progression, in an
attempt to integrate the available information within a global model
that describes the contribution of these molecular changes to the
genesis and progression of B-cell lymphomas.
(Blood. 2003;101:1220-1235) Although studies in experimental models and
analyses of virus-induced cell transformation have shown that cell
cycle subversion is a key step in tumorigenesis, the available
information on human tumors has only recently reached the critical
threshold of knowledge that allows a reasonably clear understanding of
the mechanisms of cell cycle inactivation and their contribution to the
genesis and progression of human cancer. Here, we have chosen B-cell
lymphoproliferative lesions on the understanding that the accumulation
of data concerning alterations in specific key genes makes it possible
to propose a general model that describes the role of these specific
alterations in cell cycle regulators in the initiation and progression
of these tumors.
Lymphoma/leukemia is a group of different types of cancer of the
lymphoid system, in which numerous entities feature distinctive molecular alterations (Table 1).
The most frequent types of lymphoma are collectively denominated B-cell
lymphomas (BCLs), a term that encompasses different entities with
variable clinical behavior and diverse molecular features.
Nevertheless, in general terms, it is possible to segregate BCLs into 2 main groups, defined as low- and high-growth fraction lymphomas that
roughly overlap with previous definitions of low- and high-histologic
grade.
Low-growth fraction BCLs, including follicular lymphoma (FL), marginal
zone lymphomas (MZLs), mantle cell lymphoma (MCL), and B-cell chronic
lymphocytic leukemia (B-CLL), are distinguished by a relatively low
proliferative index, small cell size, formation of large tumoral masses
in lymph nodes, bone marrow or extranodal locations, and a paradoxical
combination of advanced clinical stages associated with low clinical
aggressivity (for a review see Seng and Peterson32 and
Capello and Gaidano33). This clinicopathologic presentation seems to be the final consequence of significant advantages to cell accumulation as a result of alterations in apoptosis
regulators rather than in cell cycle control genes. The situation is
the opposite of that commonly observed in high-growth fraction BCLs,
including large B-cell lymphoma (LBCL) and Burkitt lymphoma (BL), in
which an increased proliferative index and larger cell size are
associated with more frequently localized clinical stages but a higher
clinical aggressivity, as a consequence of alterations in cell cycle
regulators such as BCL6 or c-Myc that usually occur in combination with
the more common defects in apoptosis.
A fraction of both low- and high-growth fraction lymphomas are
characterized by the acquisition of additional alterations in cell
cycle control, usually involving cyclin-dependent kinase inhibitors
(CKIs), such as p16INK4a, p21CIP1, or
p27KIP1. These tumors, irrespective of their histologic
grade, show an increased clinical aggressivity and more frequent
treatment resistance.
Alterations in genes controlling apoptosis have been recognized in
most of these tumors, although the nature of the observed changes seems
to be more complex than initially expected. Apoptosis can be initiated
in cells by 2 alternative convergent pathways (reviewed in
Igney and Krammer34): the "extrinsic" pathway
involves death receptors, such as tumor necrosis factor (TNF)
receptors or FAS, whose binding to their ligands leads to the
activation of caspase-8. The mitochondrial or "intrinsic" pathway
is thought to be triggered by the translocation into mitochondria of
BCL2 family members, which causes alterations in mitochondrial
permeability and the consequent release of cytochrome c, which,
in association with apoptotic protease-activating factor-1
(APAF1), activates caspase-9 (Figure 1).
Caspases-8 and -9 (initiator caspases) both subsequently activate
caspases-3, -6, and -7 (executioner caspases), which, in turn, cleave
substrates involved in the regulation of cell death. Alterations in the
proteins involved in these pathways could lead to tumor initiation;
moreover, the suppression of apoptosis facilitates the accumulation of
further oncogenic lesions, eventually leading to uncontrolled
proliferation.
BCL2 protein family
Chromosomal translocations involving the BCL2 gene are the characteristic type of genetic alteration of follicular lymphoma. The translocation t(14;18)(q32;q21), which is present in the large majority of FL cases (70%-90%), places BCL2 under the control of the immunoglobulin heavy chain (IgH) Eµ enhancer, leading to high expression of the BCL2 protein.1-7 Chromosomal breakpoints occur in 3'-noncoding regions of BCL2 locus and cluster in 3 regions: the major breakpoint region (MBR) (50%-70% of translocations), the intermediate cluster region (icr), and the minor cluster region (mcr).8,9 Generally, close associations have been found between the presence of translocation and the expression of BCL2 protein, although in some cases BCL2 expression seems to be independent of translocations.35-37 The absence of BCL2 expression in some FL cases suggests that tumoral cells may acquire apoptosis inhibition through mechanisms other than that of BCL2 overexpression; for instance, an important role has been postulated for BCL-XL.38 In fact, BCL2 overexpression alone is apparently not sufficient to induce a malignant phenotype, because clonal BCL2-Ig rearrangement products are detectable in normal B cells.39 Moreover, in transgenic mice mimicking t(14;18), BCL2 overexpression results in prolonged B-cell survival without an increase in cell cycling; as a consequence, these mice are susceptible to developing autoimmune diseases and follicular hyperplasia40-43 that progresses to malignant large-cell lymphoma only after a long latency and through the acquisition of secondary alterations.42 Therefore, other oncogenic events in addition to BCL2 deregulation appear to be necessary in the genesis of FL. As a final step, when alterations in key cell cycle regulators, such as p53, p16INK4a, or c-myc, are added to the initial antiapoptotic lesions, FL undergoes progression to more aggressive variants.44-48 A paradigm of a neoplasm caused by a failure in the mechanisms regulating apoptosis without an increase in cell proliferation is provided by B-cell chronic lymphocytic leukemia. Data obtained by different experimental approaches has demonstrated that the nondividing cells that constitute the hallmark of this entity carry on an increased expression of the antiapoptotic proteins BCL2 (in virtually all cases) and MCL1 (in approximately one half of the cases)49-52 and show down-regulation of the proapoptotic gene BID, as has been observed in expression profiling experiments.50 NF-  B (nuclear factor B) refers to dimeric
transcription factors belonging to the REL family (for a review see
Karin and Lin53). Studies in mice defective in NF-B
activation suggest a role for this family in adaptive immunity,
inflammation, and lymphoid organ development.54 Another
function assigned to these transcription factors is the inhibition of
apoptosis: NF-B induces the expression of antiapoptotic factors such
as the inhibitor of apoptosis proteins (IAP),
c-FLIP, and TRAF1-2, as well as members of the
BCL2 family such as BCL-XL and
A1.53
Mammals express 5 REL proteins, encoded by the genes RELA,
RELB, c-REL, NFKB1, and
NFKB2, whose activity is regulated by specific inhibitors
(I The IAP gene family encodes a group of proteins involved in the suppression of programmed cell death, in addition to other cellular functions. Their ability to suppress apoptosis is mediated, at least in part, by their ability to block caspase activity. Some IAPs (XIAP, c-IAP1, c-IAP2) bind and directly inhibit certain caspases (-3, -7, and -9)65,66 and can act as E3-ligases, catalyzing the ubiquitination of the caspases they bind.67,68 IAPs may also have caspase-independent functions, such as cell cycle regulation. In mucosa-associated lymphoid tissue (MALT) lymphomas, the most common translocation is t(11;18)(q21;q21), which occurs in 30% to 50% of these lymphomas.12-17 The genes involved in this translocation are API2 (c-IAP2) on 11q21, a member of the IAP family with caspase-inhibitory functions, and MLT1 (on 18q21), encoding the human paracaspase (a protein with certain sequence similarity to caspases whose precise function is not fully understood).69 The translocation results in a chimeric transcript encoding an API2/MLT1 fusion protein, whose action may lead to increased inhibition of apoptosis and, therefore, confer a survival advantage on tumoral cells.70 BCL10, an apoptosis-regulatory molecule containing an amino-terminal
caspase-recruitment domain, is overexpressed as a result of
t(1;14)(p22;q32), a translocation that is also recurrently detected in
a group of MALT lymphomas.10,11 In normal cells, BCL10
weakly promotes apoptosis, induces NF- Death receptors: FAS FAS (CD95, Apo-1) is a death receptor belonging to the TNF-receptor family. The binding of FAS to its physiologic ligand (FASL) leads to the assembly of a death-inducing signaling complex, which consists of trimerized FAS, Fas-associated via death domain (FADD), and procaspase-8. When recruited to this complex, caspase-8 is activated by autocleavage.FAS-induced apoptosis mediates the process of negative selection of B cells within the germinal center. Additionally, it has been suggested that FAS acts as a tumor suppressor gene. Approximately 20% of BCLs derived from germinal center or postgerminal center B cells (FL, MALT, LBCL, MM, HL) have somatic mutations in the FAS gene,78-82 which are especially frequent in extranodal lymphomas. Most of these mutations are deleterious and mainly affect the death domain, giving rise to mutant proteins that may behave as dominant-negative forms. In addition, germline mutations of FAS are associated with BCLs in both mice and humans. The mouse strain MRL/lpr-lpr, harboring an inactivating mutation in the FAS gene, develops lymphadenopathy and is prone to autoimmunity and the development of BCL.83 Germline mutations of FAS in humans lead to the autoimmune lymphoproliferative syndrome, which is characterized by symptoms that are similar to those in MRL/lpr-lpr mice and by a high predisposition to the development of BCL.84 FAS mutations have not been detected in BCLs derived from immature or pregerminal center B cells (B-cell acute lymphoblastic leukemia [ALL], MCL, B-CLL).79 However, the FAS apoptotic pathway might be disrupted in these lymphomas through different mechanisms. B-CLL cells show down-regulation of FAS and are resistant to FAS-induced apoptosis85,86; this may contribute to the extended in vivo survival of B-CLL cells. Similarly, MCL cells express low or null levels of FAS and high levels of CD40, thereby favoring the CD40 cell survival pathway, and exogenous FAS ligand has no effect on MCL cells.87 Other alterations observed in low-growth fraction lymphomas The hallmark of mantle cell lymphoma is t(11;14)(q13;q32); this translocation juxtaposes the cyclin D1 gene with an IgH enhancer,18,19 resulting in up-regulation of cyclin D1. Virtually 100% of MCLs overexpress cyclin D1, in most cases as a consequence of a t(11;14).20,21 Despite the role of cyclin D1 as a positive regulator of G1-phase progression, cyclin D1 expression in MCL is not related to proliferative activity; moreover, overexpression of cyclin D1 in Eµ-cyclin D1 mice is not sufficient to promote malignant transformation, although it strongly cooperates with other oncogenes such as myc alleles.88 These observations imply that additional alterations in MCL development are needed, although the precise nature of these molecular changes has not been completely defined. Gene expression profiling in MCL has suggested the existence of a broad spectrum of alterations in pathways regulating apoptosis, including the mitochondrial apoptotic pathway (up-regulation of BCL2, down-regulation of cytochrome C1 and caspase-9) and death-receptor signaling pathways (down-regulation of FADD, DAXX, and RAIDD).89 A different study found down-regulation of FAS and resistance to FAS-induced apoptosis in MCL cells (see "Death receptors: FAS").87 At the same time, several genes stimulating cell cycle progression were found to be up-regulated (CDK4, MDM2, SKP2, myc, E2F5/DP2, some growth factors and their receptors).89 Ataxia telangiectasia mutated gene (ATM), a kinase involved in p53 activation in response to DNA damage, is inactivated by mutation in a significant proportion of MCLs.90 A subset of MCL has been shown to accumulate alterations in p16INK4a and p53, leading to the generation of blastoid variants characterized by higher proliferative activity and more aggressive clinical behavior (see "Alterations in the Rb pathway in lymphomas").A subset of MM also features the t(11;14) translocation and displays overexpression of cyclin D1.91 In addition, cyclin D1 expression is frequent in hairy cell leukemia (HCL), although it is often weaker than it is in MCL, and it appears to be unrelated to translocations or amplification of the cyclin D1 gene.92 Alterations in the ATM gene (loss of heterozygosity [LOH] and mutations, ~15% each) have also been described in a group of B-CLL cases and are associated with impaired p53 function and resistance to the induction of apoptosis93-97; p53 itself is mutated in a similar percentage of B-CLL tumors.98 p53 dysfunction because of p53 or ATM mutation is an adverse prognostic factor in B-CLL99 and is independent of known predictors of poor outcome (CD38 expression and absence of IgVH mutations100). Interestingly, p53 dysfunction occurs exclusively in the subset of B-CLL with unmutated IgVH.99 PAX5, a member of the paired-box gene family, encodes a B-cell-specific transcription factor that regulates B-cell genes (CD19, Ig genes) and plays a key role in B-lymphoid differentiation. In addition, PAX5 stimulates B-cell proliferation and is able to transcriptionally repress p53 in vitro.101 PAX5 is juxtaposed with the IgH locus by the t(9;14)(p13;q32) translocation, which is characteristic of a subset of LPLs23,24 and has rarely been detected in other BCLs such as splenic marginal zone lymphoma (SMZL).102 The inappropriately increased expression of PAX5 in terminally differentiated B cells, in which this gene is normally down-regulated, may contribute to the pathogenesis of LPL.
In the case of lymphomas with a high-growth fraction, the most common chromosomal translocations seem to affect genes involved in proliferation control such as BCL6, in LBCL, or c-myc, in BL. Contribution of BCL6 to lymphomagenesis BCL6 acts as a multifunctional regulator involved in cell cycle control and other critical cell functions such as lymphocyte differentiation and immune response (Figure 2). It was initially identified because of its involvement in chromosomal translocations affecting 3q27, present in a group of FLs and LBCLs.103 Although BCL6 mRNA can be detected in different cell types,104,105 the protein seems to be expressed at higher levels in lymphocytes. Therefore, the oncogenic properties of BCL6 have mainly been explored in the lymphoid system, where it is expressed by B and T cells in the germinal center, isolated cells in the lymph node interfollicular area, and cortical thymocytes.106-108 Knockout mice studies have demonstrated that BCL6 is required for germinal center formation and T-cell-dependent antigen responses.109 The selective expression of BCL6 by germinal center B cells has led to its use as a surrogate marker for malignancies derived from the germinal center; thus, BCL6 is expressed in those tumors assumed to arise from follicular center cells, such as FL (almost 100%), BL (100%), a majority of LBCLs (> 80%), and nodular lymphocyte predominance-Hodgkin lymphoma (NLP-HL) (> 80%).106-108 In general terms, BCL6 expression is a finding associated with cells with a high proliferation index. Thus, BCL6 is not expressed by low-growth fraction lymphomas, with the exception of FL, in which BCL6 is detected in proliferating cells and down-regulated in the interfollicular compartment, where the growth fraction is also diminished. A similar exception is provided by NLP-HL, in which proliferating tumoral cells are distinguished by BCL6 expression. In general terms, the pattern of expression of BCL6 in normal and tumoral lymphoid tissue is the opposite of that of p27KIP1; thus, it seems that BCL6, probably as a consequence of its ability to down-regulate p27KIP1 expression,110 is a key marker in B cells leading to proliferation (Figure 3).
BCL6 rearrangements (chromosomal translocations involving the BCL6 5'-noncoding region in 3q27) occur at a frequency of 20% to 40% in large B-cell lymphoma and 6% to 14% in FL.25-27 In contrast, rearrangements of BCL6 (as well as those affecting BCL2 or c-myc) are very rare in primary mediastinal B-cell lymphoma, which suggests that this tumor is a separate type of LBCL arising from different pathogenetic mechanisms.111 These translocations contribute to BCL6 deregulation; however, we know that the level of BCL6 expression seems to depend on the partner involved in the translocation, because tumors in which BCL6 is translocated to an Ig locus express higher levels of BCL6 mRNA than those with non-Ig/BCL6 translocation, and also that overexpression of BCL6 is often independent of chromosomal translocations.112 In this respect, it has recently been claimed that somatic mutations involving the 5'-noncoding region of the BCL6 gene can contribute to the deregulation of BCL6 expression.113 In LBCL, somatic mutations in the major mutational cluster have been described as playing a role in the regulation of BCL6 expression. Mutations within the 423 to 443 hotspot in the first intron of BCL6 are associated with increased protein levels, suggesting that this region may include a regulatory element whose mutation may modify the binding of hypothetical BCL6-regulating transcription factors. The BCL6 gene encodes a sequence-specific transcriptional repressor.114-117 Expression profiling of B-cell lines in which BCL6 was positively or negatively modulated revealed that BCL6 represses a group of genes involved in B-cell activation and terminal differentiation (such as Blimp-1) and cell cycle control (cyclin D2, p27KIP1), and it has been hypothesized that this indirectly induces c-myc expression.110 Therefore, the lack of germinal center formation, as observed in BCL6 knockout mice,109 could be at least partially a consequence of the absence of the proliferative signal that is dependent on BCL6. Blimp-1 (B-lymphocyte-induced maturation protein 1) is a transcriptional repressor with a key role in the differentiation of B cells into plasma cells.118 One of the targets of Blimp-1 repression is c-myc.119 In vitro studies have shown that inhibition of BCL6 function induces Blimp-1 and down-regulates c-myc expression, causing cell cycle arrest in G1.110 Conversely, it might be hypothesized that overexpression of BCL6 because of translocations or somatic mutations could indirectly activate c-myc through repression of Blimp-1 by BCL6, although this has not been formally demonstrated in human tumors. The altered expression of BCL6 could also repress genes involved in apoptosis, thereby favoring neoplastic cell growth. One candidate target is PDCD2,120 previously found to be associated with programmed cell death in thymocytes. However, the role of BCL6 in apoptosis is controversial because the report cited earlier, and others, suggest that BCL6 may be an inhibitor of apoptosis,121,122 whereas other studies suggest that it induces cell death. For example, it has been proposed that AFX (a forkhead transcription factor) activates apoptosis by induction of BCL6, which in turn represses BCL-XL.123 This dual role of BCL6 in the regulation of apoptosis could be dependent on factors such as cell type or level of expression. BCL6 has also been identified as a potent inhibitor of senescence in murine embryo fibroblasts and primary B cells, making cells unresponsive to negative proliferation control by the p19ARF-p53 pathway through a mechanism mediated by up-regulation of cyclin D1.124 This finding may be potentially relevant, but we need to bear in mind that cyclin D1 expression in B cells is mainly restricted to MCL. The prognostic significance of 3q27 translocation and BCL6 expression has been analyzed in different series. BCL6 rearrangement has been described as an independent marker of favorable clinical outcome in LBCL.26 The partner in BCL6 translocation is predictive of survival, because non-Ig/BCL6 translocations are an indicator of poor prognosis in LBCL compared with Ig/BCL6.125 Most studies coincide in showing that a high level of BCL6 expression, as determined by real-time polymerase chain reaction (PCR) or immunohistochemistry, is a favorable prognostic marker. These observations may be linked by the finding that non-Ig/BCL6 translocations lead to much lower BCL6 mRNA levels than do Ig/BCL6 translocations.112 Mutations in the 423 to 443 cluster, which are associated with high BCL6 levels, are also associated with a better clinical outcome.113 The increased expression of BCL6 was one of the features that made it possible to define a subset of germinal center B-cell-like LBCLs, characterized by lower aggressivity, increased frequency of c-REL amplification, and translocations involving the BCL2 gene.57,126,127 Thus, Rosenwald et al57 have recently identified 3 different LBCL subgroups (germinal center B-cell-like, activated B-cell-like, and type 3 LBCL) through the use of gene expression profiling. The different clinical behavior of the germinal center B-cell-like group and the fact that some molecular alterations appear to occur exclusively in this concrete subset may support the idea that this LBCL subgroup actually represents a distinct entity with specific mechanisms of transformation. The c-Myc transcription factor c-Myc, a helix-loop-helix leucine zipper transcription factor, has been proposed as being involved in multiple cellular functions such as cell cycle regulation, apoptosis, cell growth, metabolism, cell adhesion, and differentiation. However, much of the information available is still controversial, and, to some extent, the precise involvement of c-Myc in these functions might be cell type- and context-dependent (reviewed in Eisenman,128 Boxer and Dang,28 Dang,129 and Amati et al130). The ability of c-Myc to bind to specific DNA sequences (E-boxes) and activate transcription requires heterodimerization with Max. Max also heterodimerizes with other Myc family proteins, such as Mad or Mxi1; Mad-Max dimers mediate transcriptional repression in E-boxes and might antagonize the activity of Myc-Max, at least in some promoters.131,132 Myc-Max complexes can also exert repressing activity on initiator (Inr) elements, in conjunction with Miz-1.133Myc promotes proliferation through the induction of genes involved in cell cycle control such as CDK4, Id2, CDC25A, and cyclins D1, D2, A, and E. Additionally, Myc suppresses growth-arresting genes such as p15INK4b, p21CIP1, GADD45, or GAS1.128-130,133-135 p27KIP1 is negatively regulated by Myc at different levels, including transcriptional repression,136 the increase of its degradation, and its sequestration by CDK4/cyclin D2 (Figure 2). c-Myc also induces cellular immortalization, a function that may be mediated by induction of the catalytic subunit of telomerase.137 Overexpression of c-Myc in primary cells results in cell cycle arrest or apoptosis, in contrast to what happens in immortalized cells. High levels of expression of c-Myc result in induction of p19ARF, which sequesters MDM2, leading to activation of p53-mediated arrest or apoptosis.138 Other targets that contribute to Myc-mediated apoptosis may be FAS, FASL, and BAX.28 The ability of Myc to induce apoptosis explains why, in transgenic mice, tumors overexpressing Myc frequently select for alterations that neutralize its apoptotic program through inactivation of the p19ARF/p53 pathway139 or BCL2 overexpression.140 The c-myc gene is subject to complex transcriptional and
posttranscriptional regulation. Four promoters have been identified, although one of them (P2) usually contributes to 80% to 90% of c-myc RNA in normal cells.28 Expression of
c-myc is positively regulated by multiple factors, such as
BCL6,110 epidermal growth factor (EGF),
platelet-derived growth factor (PDGF), and interleukin 7 (IL-7),141 and negatively controlled by
Blimp-1,119 transforming growth factor The c-myc gene is translocated to the Ig loci in
virtually all Burkitt lymphomas.28-31 The most frequent
translocation, c-myc/IgH (t(8;14)(q24;q32)), is detected in
about 80% of BLs. Each of the variant translocations, t(2;8)(p12:q24)
and t(8;22)(q24;q11), involving IgK and IgL,
respectively, occur at a frequency of approximately 10%. These or
other translocations involving c-myc have also been detected
in LBCL (6%)143 and other hematologic malignancies, such
as T-cell ALL and MM. These translocations are believed to place
c-myc under the control of an intronic and/or 3'
Ig enhancer, leading to a deregulated expression from the
translocated allele (the normal allele remains silent). This expression
could be explained by a combination of events, including a switch from
P2 to P1 promoters and the release of the block on transcription
elongation. NF- Most translocated c-myc alleles in BL are subjected to somatic hypermutation.145 Mutations tend to cluster in either the exon 1-intron 1 region, where they may cancel the block on transcription elongation, or the transactivation domain (Thr58 is a hot spot), possibly interfering with phosphorylation and thereby contributing to the stabilization of the protein. Similarly distributed somatic mutations were detected in LBCL (32%).146 Deregulation of c-myc by alternative mechanisms, such as
amplification, occurs in diverse types of tumors and has been
implicated in the pathogenesis of these diseases; in LBCL
c-myc amplification has been found in up to 16% of
cases.56 Increased expression or activation of upstream
c-myc regulators (NF- Alterations in c-myc seem to constitute one of the primary events in malignant transformation in BL, but they could also be a secondary event in tumor progression. In fact, translocations of c-myc have been observed in transformed FL.47,48 According to experimental models, overexpression of Myc alone may not be sufficient to induce cellular transformation. Eµ-myc mice develop clonal B-cell malignancies (not comparable with BL, however) that usually accumulate alterations in the p19ARF/p53 pathway or BCL2, thereby allowing the cancellation of Myc-induced apoptosis.139 This mimics the situation observed in samples of progressed FL and aggressive B-cell lymphoma with double c-myc and BCL2 translocation, in which simultaneous BCL2 and c-Myc expression gives a critical advantage to the tumoral cells.47,48 There are few conclusive studies regarding the relationship between c-Myc and clinical or biologic variables in lymphomas, and there is some variability in the findings among these reports concerning protein levels, cell distribution, and subcellular localization. Nevertheless, these analyses seem to coincide in showing that c-Myc overexpression is common in aggressive lymphomas and appears to be related to advanced clinical stage, high International Prognostic Index, or shorter overall survival.147-149
Both low- and high-growth fraction lymphomas can evolve to highly aggressive tumors; the process takes place through the acquisition of alterations in the major tumor suppressor pathways, most frequently affecting CKI. In fact, inactivation of CKI is a marker of highly aggressive lymphomas, irrespective of their histologic grade. CKI inactivation takes place in a concerted manner to confer a proliferative advantage to tumoral cells and, at the same time, determines increased treatment resistance. The G1/S transition of the cell cycle is regulated by 3 main pathways that might be altered in virtually 100% of aggressive tumors and that are represented by the proteins p16INK4a-cyclin D-CDK4-Rb, p14ARF-MDM2-p53-p21CIP1, and p27KIP1-cyclin E-CDK2 (reviewed in Sherr150). Alterations in the Rb pathway in lymphomas In normal cells, the transition through the restriction point is negatively regulated by the retinoblastoma (Rb) protein (Figure 4A). Rb binds to transcription factors (E2Fs) whose activity is necessary for the expression of S-phase genes, and it assembles a transcriptionally repressing complex that keeps E2F-responsive promoters inactive. Under conditions of mitogenic stimulation, accumulation of D-type cyclins allows the formation of active CDK4/6-cyclin D complexes, which phosphorylate and inactivate Rb, thus promoting E2F-mediated transcription and subsequent progression through the cell cycle. An additional level of regulation is provided by the INK4 (inhibitors of cdk4) family of CKI (p16INK4a, p15INK4b, p18INK4c, p19INK4d). These 4 homologous proteins inhibit the kinase activity of CDK4/6 by preventing its interaction with the activating cyclins D. The integrity of this regulatory cascade, termed the "Rb pathway" (INK4-CDK4,6/cyclin D-Rb-E2F), appears to be compromised in most human cancers. This inactivation can be achieved by an increased activity of CDK-cyclin complexes and/or by inactivation of the tumor suppressor genes INK4a or Rb.
The distribution of Rb protein in reactive lymphoid tissue follows a pattern that is parallel to that of Ki67 (a proliferation marker), with preferential expression in most germinal center B cells and cortical thymocytes.151 This normal regulation of Rb in relation to proliferative activity is frequently preserved in different types of lymphoma, in which genetic alterations of the Rb gene appear to be relatively rare.152-154 Levels of Rb are low in low-growth fraction BCLs, whereas they are higher in most high-growth fraction tumors.151,155 NLP-HL also displays this direct correlation between Rb and proliferation,156 and in blastoid MCL the expression and phosphorylation level of Rb are higher than in classical types.152 A deviation from this pattern, consisting of partial or total loss of Rb expression in highly proliferative tumors, was detected in a group of high-growth fraction non-Hodgkin lymphomas (NHLs)151,157 and classical HL156; this may be, at least in part, a consequence of genetic alterations, which have been found at low frequencies in different lymphoid malignancies. Loss of Rb was found to be an adverse prognostic factor in LBCL, in which there was a correspondence between high Rb protein levels and extended overall survival time,158 and in HL, in which Rb loss was related to failure to achieve complete remission159; monoallelic deletions of Rb predict poor outcome in MM.160 Notably, the Rb-like p130 protein is mutated in most cases of endemic BL.161 Of the 3 D-type cyclins (D1, D2, D3), cyclin D3 is the most ubiquitously expressed in lymphoid tissue. It is detected mainly in proliferating lymphocytes, either in germinal centers or interfollicular areas.162,163 Several observations point to a possible oncogenic role of cyclin D3 in lymphomagenesis. Immunohistochemical analysis of aggressive BCL revealed that a significant number of these tumors overexpressed cyclin D3, a finding that was more frequent in BL.162 Recent work points to an association between high levels of cyclin D3 expression and poor clinical outcome in LBCL.164 It is interesting to note that, in addition to the direct activation of CDK4/6, cyclin D3 appears to play another role in the promotion of cell proliferation, ie, the indirect activation of CDK2-cyclin E achieved by the sequestration of p27KIP1 (see "p27KIP1 alterations in lymphomas"). Recent data suggest that cyclin D3 overexpression may have a genetic basis in some cases, because t(6;14)(p21;q32) translocations involving cyclin D3 and IgH genes have been detected in several hematologic malignancies (myeloma, plasma cell leukemia, LBCL, SMZL) and result in the deregulated expression of cyclin D3.165 In contrast, the level of cyclin D2 expression is low in normal and tumoral lymphoid tissue (except in B-CLL and LPL in which it is often overexpressed166), and cyclin D1 is virtually absent167 (with the exception of MCL, HCL, and a subset of MM; see "Other alterations observed in low-growth fraction lymphomas"). Molecular studies concerning the status of CDK4/6 in lymphomas are scarce; amplification of the CDK4 gene has been identified in 11% of LBCLs,56 and translocations affecting CDK6 (t(7;14) or t(2;7)) have been described in splenic lymphoma with villous lymphocytes.168 Despite the fact that the INK4 proteins share structural and functional homology, only p16INK4a has gained credence as a bona fide tumor suppressor gene in vivo. The p16INK4a and p15INK4b genes are located in 9p21, which is, after p53, the most frequently altered locus in human cancer and which also encodes p14ARF; in contrast, p18INK4c and p19INK4d are very rarely altered in human tumors, including lymphomas.169,170 In reactive lymphoid tissue, p16INK4a protein is detected
in all compartments, with a slight increase in the most proliferative ones (germinal centers, interfollicular areas) and a decrease in the
mantle zone, which mainly consists of resting
lymphocytes.171 Low-growth fraction BCLs display normal
p16INK4a expression by small- and medium-sized tumoral
cells. There is a dramatic difference in high-growth fraction BCLs,
more than 50% of which exhibit partial or total loss of expression of
p16INK4a protein by tumoral cells. This finding is often
associated with alterations in the p16INK4a gene
(Table 2). Thus, although
p16INK4a alterations are rare in low-growth
fraction BCLs (< 5%), genetic or epigenetic inactivation of
p16INK4a occurs in 30% to 50% of high-growth
fraction BCLs,173,178,179,183,184 predominantly by 9p21
deletion/LOH or promoter hypermethylation (the most frequent mechanism
in LBCL); point mutations of p16INK4a are
infrequent. It has been shown that p15INK4b is
either frequently codeleted with p16INK4a or
hypermethylated at variable frequency and that
p15INK4b hypermethylation can occur
independently of that of
p16INK4a.172,181,185 Inactivation
of p16INK4a may also play a role in the development of HL,
because many HL cases show selective loss of p16INK4a
expression by Reed-Sternberg (RS) cells; hypermethylation of the
p16INK4a promoter appears to be the underlying
molecular mechanism in most of these tumors.182
There is ample evidence supporting a role for
p16INK4a inactivation in the transformation of
low-growth fraction lymphomas into their aggressive variants. The
histologic progression of FL to aggressive large cell lymphoma is
frequently accompanied by 9p21 deletions (absent in the low-grade
tumor) that often result in reduction or loss of p16INK4a
expression.44 In MCL, p16INK4a
deletions are associated with aggressive variants,174 a
finding that interestingly suggests the possibility that cyclin D1
overexpression and p16INK4a inactivation might
not be completely redundant alterations. In composite tumors (lymphomas
consisting of a low-grade The relatively high frequency of p16INK4a/Rb
alterations Alterations in the p53 pathway in lymphomas p53 is a transcription factor that induces the expression of genes involved in cell cycle arrest or apoptosis in response to a variety of toxic or oncogenic stimuli, the final cellular response depending on the biologic context. Negative regulation of cell cycle progression by p53 is partially mediated by induction of p21CIP1, a CKI of the CIP/KIP family that neutralizes the kinase activity of CDK2-cyclin E complexes. One of the target genes of p53 is MDM2, which inhibits p53 and targets it for degradation by virtue of its E3-ubiquitin ligase activity. In response to DNA damage or hyperproliferative stimulation, the p53-MDM2 interaction is disrupted by phosphorylation or antagonized by p14ARF induction, respectively, resulting in the activation of p53.150 This "p53 pathway" is also frequently altered in most human cancers, either by inactivation of the tumor suppressor genes p14ARF or p53 or by hyperactivation of the MDM2 oncogene. In fact, p53 is the most frequently mutated gene in human cancer (> 50% of all cases).Mutations of p53 are detected in 17% to 25% of cases
of LBCL and BL.178,180,186-190 This frequency is
relatively low compared with other types of cancer but is still
significantly higher than that observed in most low-growth fraction
BCLs, which supports the hypothesis that p53 inactivation is
one of the events leading to high-grade progression (Table
3). Mutations of p53 in
lymphomas tend to be clustered in conserved regions that are part of
the sequence encoding the DNA binding domain. In aggressive BCL, the inability of mutant p53 to transactivate its target genes is reflected by the p53+p21
Missense mutations of p53 usually result in the
stabilization of the protein; therefore, increased levels of p53 are
typically detected in association with p53
mutations.201 Although this is essentially true in
low-growth fraction lymphomas such as B-CLL, FL, and MCL, the
relationship between p53 mutation and expression in LBCL and
BL is not a direct one,188,190 suggesting the existence of
alternative mechanisms for the stabilization of p53. Overexpression of
the p53 protein is relatively common in high-growth fraction NHL (de
novo as well as those that progress from low grade)202 but
not in low-growth fraction tumors. However, only a fraction of the NHL
cases overexpressing p53 have an underlying p53
mutation.188,190 Moreover, some NHLs with a wild-type
p53 gene have the
p53+MDM2 There is firm evidence that inactivation of p53 plays a key role in the progression of low-grade lymphomas. Mutations of p53 are strongly associated with large cell transformation of MALT lymphomas193 and FL45,46 and with blastoid variants of MCL.195 They are frequently detected in progressed tumors but appear at lower frequencies in their low-grade counterparts. In any case, and independently of the presence of morphologic signs of progression, p53 mutations and stabilization of the p53 protein are associated with more aggressive clinical behavior and treatment resistance in all histologic types of low-growth fraction lymphomas, such as B-CLL,98 FL, MZL, and MCL.194,195 The contribution of p53 inactivation to the aggressive phenotype has also been observed at the clinical level in LBCL, in which p53 overexpression or mutation has been reported as being associated with lower survival probability.187,191,206 The relatively low incidence of p53 mutations in lymphomas has prompted the examination of possible alternative mechanisms of inactivation of the p53 pathway. Mutation, deletion, and hypermethylation of p21CIP1 have only very rarely been described in BCL, although recent data show an increased incidence of p21CIP1 promoter hypermethylation associated with poor prognosis in ALL.207 The p53-activating kinase ATM is mutated in B-CLL and MCL (see "Other alterations observed in low-growth fraction lymphomas"). Overexpression of MDM2 may represent a mechanism of inactivation of p53 that is not dependent on p53 mutations. This might be particularly true in HL, a tumor that consistently displays accumulation of the MDM2 protein in RS cells205,208 and at the same time exhibits an especially low frequency of p53 mutations. Overexpression of MDM2 also occurs at significant frequencies in leukemias209 and NHL,180,210,211 suggesting a contribution to tumorigenesis that is further supported by the association between high levels of MDM2 and shorter overall survival in LBCL,158 low-growth fraction NHL,210 and treatment resistance in ALL.212 It is not completely clear whether MDM2 overexpression has a genetic basis: several studies coincide in finding no amplifications of the MDM2 gene in lymphomas.213 However, amplifications of the 12q13 region, which resulted in an effective increase in the MDM2 gene copy number, were detected in 14% of LBCLs,56 and gains in 12q with increased MDM2 copy number have been described in HL.199 Alterations of the p14ARF gene that result in the loss of its expression are relatively rare in LBCL and BL.186,214 Unlike p16INK4a, p14ARF promoter hypermethylation has rarely been found; point mutations are very infrequent (0%-4%); and monoallelic or biallelic deletions at 9p21 potentially affecting p16INK4a and p14ARF have been observed in 10% to 20% of cases. Consistent with these findings, only a small group of lymphomas lack p14ARF expression in tumoral cells, whereas the rest show variable levels of the p14ARF protein.214 p27KIP1 alterations in lymphomas At the G1/S transition, mitogen-dependent phosphorylation of Rb by CDK4/6-cyclin D is shifted to mitogen-independent action of CDK2-cyclin E complexes, which, in addition to triggering DNA replication, are able to phosphorylate Rb further, thus contributing to the irreversibility of the transition to S phase. Negative regulation of CDK2-cyclin E activity is mediated by the CIP/KIP family of CKI (p21CIP1, p27KIP1, p57KIP2). These proteins also bind CDK4-cyclin D, but these complexes may preserve kinase activity; CIP/KIP proteins may even be required for the assembly of active CDK4 holoenzymes. Therefore, it has been postulated that the sequestration of CIP/KIP may be another function of CDK4-cyclin D, which would facilitate the activation of CDK2-cyclin E.150Multiple roles have been attributed to p27KIP1, not
only as a mediator of G1 arrest in response to TGF- Biallelic genetic alterations of p27KIP1 in lymphomas and other tumors are very rare.216-219 However, there is evidence that p27KIP1 behaves as a haploinsufficient gene for tumor suppression,220 in such a way that a reduction in its levels (resulting from monoallelic silencing,221 increased degradation, or other mechanisms) may be sufficient to contribute to tumorigenesis. In reactive lymphoid tissue, the expression of p27KIP1 is inversely related to proliferation219,222-224 (Figure 3). Strong p27KIP1 expression is detected in quiescent cells (mantle lymphocytes, medullary thymocytes), whereas p27KIP1 is down-regulated in proliferating cells (germinal center B cells, large interfollicular lymphocytes, and cortical thymocytes). As a general rule, the expression of p27KIP1 in lymphomas
follows the same inverse relationship with
proliferation.219,222-224 In low-growth fraction BCL,
p27KIP1 is strongly detected in small cells, medium-sized
cells stain more weakly, and occasional large cells are negative.
Possible exceptions are typical MCL219 and
HCL,225 in which p27KIP1 appears to be
undetectable by immunohistochemistry despite the low proliferative
index of these tumors. In contrast, most high-growth fraction BCLs do
not show p27KIP1 expression by tumoral cells (Figure 3). In
HL, p27KIP1 protein is only rarely detected in the highly
proliferative RS cells, whereas small surrounding lymphocytes preserve
p27KIP1 expression.222 Similar observations
have been made in different tumoral types, implying a role of
p27KIP1 down-regulation in tumor progression. Loss of
p27KIP1 is indicative of poor outcome (shorter survival) in
NHL, considered as a whole,224 and also in the discrete
group of MCL.226 Mechanisms underlying this
down-regulation (Figure 5) may include
transcriptional repression (p27KIP1 is a target
of c-Myc-mediated repression136) and increased
degradation, as suggested by the observation that increased expression
of SKP2 (ubiquitin ligase for p27KIP1) is positively
correlated with cell proliferation and grade of malignancy in human
lymphomas and inversely correlated with p27KIP1
expression.227 MCL and a group of LBCLs are exceptions to
this pattern, implying that there are alternative pathways regulating p27KIP1.
An unexpected finding was the observation that a group of LBCL and BL had an unusually high level of p27KIP1 expression in tumoral cells219,222-224 (Figure 3). A more detailed analysis of a large series of LBCLs228 led to the following conclusions: (1) a broad gradient of p27KIP1 expression exists in LBCL, ranging from absence of protein to overexpression; (2) there is no positive or negative correlation between p27KIP1 and proliferation in LBCL; and (3) a high level of p27KIP1 expression is an adverse prognostic factor for LBCL, strongly associated with shorter overall survival and disease-free survival. Anomalous high expression of p27KIP1 associated with a more aggressive course has also been described in B-CLL; high p27KIP1 expression levels are associated with lower spontaneous cell death rate of B-CLL cells in culture, suggesting that p27KIP1 may contribute to apoptosis impairment.229 These findings suggest that overexpressed p27KIP1 might be inactive in cell cycle inhibition and that mechanisms of p27KIP1 inactivation other than down-regulation should exist, which allowed tumoral cells to overcome the antiproliferative activity of this CKI. The previous findings and the observation that high levels of p27KIP1 in LBCL and BL were significantly related to cyclin D3 overexpression162,223 (but not to that of cyclins D1, D2, or E), suggested that p27KIP1 might be sequestered in CDK4-cyclin D3 complexes. In this context, p27KIP1 might be protected from CDK2-mediated degradation and at the same time be inactive as a CKI, because CDK4-cyclin D-KIP complexes appear to preserve kinase activity. Consistent with this hypothesis, p27KIP1 was immunoprecipitated in cyclin D3-containing complexes in BL cell lines with high levels of both proteins (Raji, BL40); part of p27KIP1 was also bound to cyclin D3 in tumor samples with intermediate p27KIP1 levels.162,223 In lymphomas overexpressing p27KIP1 and cyclin D3, both proteins were colocalized in the nucleus of most tumoral cells, in sharp contrast with the observation in reactive lymphoid tissue and all other lymphomas that expression patterns of cyclin D3 and p27KIP1 were mutually exclusive.162 These data allow us to conclude that several mechanisms operate in high-growth fraction BCL to inactivate p27KIP1. In some tumors, transcriptional down-regulation or increased degradation may predominate, causing a decrease in p27KIP1 levels. However, in a subset of aggressive lymphomas, p27KIP1 is redistributed from CDK2-cyclin E complexes, in which p27KIP1 is active as a CKI and is unstable (susceptible to CDK2-signaled degradation) to CDK4/6-cyclin D complexes, in which p27KIP1 is stabilized but inactive (Figure 5). Accumulated alterations in tumor suppressor pathways The results discussed above indicate that the inactivation of individual CKI is biologically and clinically significant and plays a major role in the progression of lymphomas. Do these individual events operate in a concerted way in the pathogenesis of aggressive lymphomas? The combined analysis of the major tumor suppressor pathways p16INK4a-Rb, p14ARF-p53, and p27KIP1-CDK2 has revealed that simultaneous inactivation of several cell cycle regulators does occur in a subset of lymphomas, bestowing an advantage on the tumor.Highly aggressive lymphomas frequently show alteration of at least one of these pathways with a significantly higher frequency than in low-grade tumors.178,186,230 Moreover, the simultaneous inactivation of the p16INK4a-Rb and p14ARF-p53 pathways occurs in a significant proportion of aggressive BCLs, mainly through 2 alternative mechanisms: (1) the combination of p16INK4a hypermethylation and p53 mutation predominates in LBCL; (2) deletions at 9p21 occur more frequently in BL, and their presence and p53 mutation are mutually exclusive. This is consistent with the prediction that 9p21 deletions normally affect both p16INK4a and p14ARF, and, thus, a single event accounts for the impairment of both pathways (in this context, the additional advantage provided by a p53 mutation would be markedly reduced). The difference between LBCL and BL suggests that mechanisms of inactivation of tumor-suppressor pathways are not "chosen" at random but depend on underlying genetic alterations. Simultaneous inactivation of both pathways predicts poor outcome in aggressive BCL230 and in MCL.186 Overexpression of p27KIP1 occurs, in most LBCL cases, in tumors with inactivation of p16INK4a and/or p53.178 This relationship is not as obvious in BL, implying a greater complexity of the mechanisms regulating p27KIP1 expression. Moreover, in LBCL, p27KIP1 accumulation is more frequent in tumors with the p16INK4a and p53 double alteration than in those with a single inactivating event. This implies that p27KIP1 sequestration is a secondary event, derived from the absence of p16INK4a and/or p21CIP1 (Figure 5). Under these conditions, p16INK4a or p21CIP1 do not compete with p27KIP1 to bind CDK4-cyclin D, there is no displacement of p27KIP1 to CDK2-cyclin E complexes and p27KIP1 remains inactive, sequestered by cyclin D-dependent complexes. Therefore, although abnormal accumulation of p27KIP1 behaves as a marker of the inactivation of p16INK4a/p53, it is not a mere "reflection" of the malfunction of these pathways. Instead, there is evidence that this mechanism of inactivation of p27KIP1 contributes by itself to the pathogenesis of the lymphoma. Thus, the accumulation of alterations in p53, p16INK4a, and p27KIP1 confers higher aggressivity on tumors, which manifests itself by increased proliferative activity and shorter overall survival. The group of tumors with the triple alteration has the highest proliferation index and a significantly worse outcome. From this we may conclude that alterations in different CKIs cooperate to give a proliferative advantage to lymphomas. In the light of the previous data, it may be worth reconsidering
the role of p14ARF. In a normal cell, p14ARF
antagonizes MDM2 and activates p53-mediated responses as a protective mechanism against hyperproliferative stimuli.150,187 To
this end, p14ARF expression is induced by
oncogene products such as c-Myc, E1A, Ras, and v-Abl. The
p14ARF promoter is responsive to the E2F-1
transcription factor, a property that links Rb to the
p14ARF-p53 pathway and allows p53 to sense and respond to
oncogenic stimulation transduced through the Rb pathway. As a
negative-feedback mechanism, wild-type p53 represses the transcription
of the p14ARF gene. A group of aggressive BCLs
(20%) abnormally overexpresses the p14ARF protein (this is
not confined to the nucleolus, as in normal cells).214
This group of cases was characterized by higher aggressivity: p14ARF overexpression was significantly related to a higher
growth fraction and shorter overall survival. Overall, these
tumors had alterations in at least one of the major tumor suppressor
pathways (p16INK4a, p53, or p27KIP1), and
p14ARF overexpression was more frequently detected in
lymphomas with simultaneous inactivation of several of these tumor
suppressor genes. This could be explained as a "normal" response of
the p14ARF gene to cell cycle malfunction in a
tumoral cell: inactivation of p16INK4a or
p27KIP1 results in increased phosphorylation of Rb by
CDK4/6 or CDK2, respectively, and active E2F-1 is generated, thereby
inducing p14ARF expression. Activated oncogenes
(Ras, Myc) also up-regulate p14ARF. Finally,
p53 mutations disrupt the p53-p14ARF
negative-feedback loop. As a consequence, p14ARF expression
reflects the degree of malfunction of the cell cycle, which, as shown
before, is related to tumoral aggressivity (Figure 6).
The mechanisms and the extent to which the physiologic
balance between cell division and cell death are disrupted in lymphoma cells determine the characteristics and evolution of the tumor. In
low-growth fraction lymphomas, cell accumulation can be achieved through the inhibition of apoptosis without a very severe deregulation of cell proliferation. In contrast, in high-growth fraction BCL, proliferation is stimulated through the coordinated action of cell
cycle regulators such as BCL6 or c-Myc. A fraction of both low- and
high-growth fraction lymphomas acquire additional changes that allow
tumoral cells to bypass the multiple mechanisms by which cell cycle
progression is inhibited in normal cells, including the tumor
suppressor pathways represented by p16INK4a-cyclin
D-CDK4-Rb, p14ARF-MDM2-p53-p21CIP1, and
p27KIP1-cyclin E-CDK2. These lymphomas have a very high
clinical aggressivity that is related to the degree of malfunction of
these pathways. Tumoral cells often undergo accumulated disruption of
more than one of these cascades, taking advantage of their simultaneous and concerted inactivation (Figure
7).
However, despite the important progress that has been made toward the elucidation of the mechanisms of lymphomagenesis, many points still need to be clarified, such as the interrelationships between BCL6, c-Myc, and p27KIP1 and the plethora of molecules and pathways that may be affected by their alterations. Gene expression profiling experiments are providing us with unprecedented information regarding new molecules and pathways involved in tumorigenesis. Whole genome analysis will surely contribute to our better understanding of the mechanisms governing the initiation and progression of lymphomas and allow the establishment of correlations between patterns of gene expression and precise biologic and clinical features.
We apologize to those many authors whose work could not be appropriately cited in this review because of space limitations. We thank Marcos Malumbres, Ana I. Sáez, Raquel Villuendas, Juan F. García, María J. Artiga, and Francisca I. Camacho for critical reading and advice and Phil Mason for his collaboration in the preparation of the manuscript.
Submitted July 8, 2002; accepted September 3, 2002.
Prepublished online as Blood First Edition Paper, September 12, 2002; DOI 10.1182/blood-2002-07-2009.
Supported by grants from the Fondo de Investigaciones Sanitarias (FIS 98/993), Ministerio de Sanidad y Consumo, Comisión Interministerial de Ciencia y Tecnología (1FD97-0431), Comunidad Autónoma de Madrid (08.1/0028/2000 1), and the Ministerio de Ciencia y Tecnología (SAF2001-0060), Spain. A.S.-A. is supported by a predoctoral fellowship from the Consejería de Educacion de la Comunidad de Madrid, Spain, and the European Social Fund.
Reprints: Miguel A. Piris, Molecular Pathology Program, Centro Nacional de Investigaciones Oncológicas (CNIO), Melchor Fernández Almagro 3, E-28029 Madrid, Spain; e-mail: mapiris{at}cnio.es.
1. Yunis JJ, Oken MM, Kaplan ME, Ensrud KM, Howe RR, Theologides A. Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. N Engl J Med. 1982;307:1231-1236[Abstract].
2.
Tsujimoto Y, Cossman J, Jaffe E, Croce CM.
Involvement of the bcl-2 gene in human follicular lymphoma.
Science.
1985;228:1440-1443 3. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell. 1986;47:19-28[CrossRef][Medline] [Order article via Infotrieve]. 4. Weiss LM, Warnke RA, Sklar J, Cleary ML. Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med. 1987;317:1185-1189[Abstract]. 5. Yunis JJ, Frizzera G, Oken MM, McKenna J, Theologides A, Arnesen M. Multiple recurrent genomic defects in follicular lymphoma: a possible model for cancer. N Engl J Med. 1987;316:79-84[Abstract].
6.
Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM.
Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation.
Science.
1984;226:1097-1099 7. Bakhshi A, Jensen JP, Goldman P, et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell. 1985;41:899-906[CrossRef][Medline] [Order article via Infotrieve].
8.
Cleary ML, Galili N, Sklar J.
Detection of a second t(14;18) breakpoint cluster region in human follicular lymphomas.
J Exp Med.
1986;164:315-320
9.
Albinger-Hegyi A, Hochreutener B, Abdou MT, et al.
High frequency of t(14;18)-translocation breakpoints outside of major breakpoint and minor cluster regions in follicular lymphomas: improved polymerase chain reaction protocols for their detection.
Am J Pathol.
2002;160:823-832 10. Willis TG, Jadayel DM, Du MQ, et al. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell. 1999;96:35-45[CrossRef][Medline] [Order article via Infotrieve]. 11. Zhang Q, Siebert R, Yan M, et al. Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32). Nat Genet. 1999;22:63-68[CrossRef][Medline] [Order article via Infotrieve].
12.
Levine EG, Arthur DC, Machnicki J, et al.
Four new recurring translocations in non-Hodgkin lymphoma.
Blood.
1989;74:1796-1800 13. Dierlamm J, Baens M, Wlodarska I, et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21)p6ssociated with mucosa-associated lymphoid tissue lymphomas. Blood. 1999;93:3601-3609.
14.
Baens M, Maes B, Steyls A, Geboes K, Marynen P, De Wolf-Peeters C.
The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation.
Am J Pathol.
2000;156:1433-1439 15. Baens M, Steyls A, Dierlamm J, De Wolf-Peeters C, Marynen P. Structure of the MLT gene and molecular characterization of the genomic breakpoint junctions in the t(11;18)(q21;q21) of marginal zone B-cell lymphomas of MALT type. Genes Chromosomes Cancer. 2000;29:281-291[CrossRef][Medline] [Order article via Infotrieve].
16.
Inagaki H, Okabe M, Seto M, Nakamura S, Ueda R, Eimoto T.
API2-MALT1 fusion transcripts involved in mucosa-associated lymphoid tissue lymphoma: multiplex RT-PCR detection using formalin-fixed paraffin-embedded specimens.
Am J Pathol.
2001;158:699-706
17.
Liu H, Ye H, Dogan A, et al.
T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10.
Blood.
2001;98:1182-1187 18. Tsujimoto Y, Jaffe E, Cossman J, Gorham J, Nowell PC, Croce CM. Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation. Nature. 1985;315:340-343[CrossRef][Medline] [Order article via Infotrieve].
19.
Tsujimoto Y, Yunis J, Onorato-Showe L, Erikson J, Nowell PC, Croce CM.
Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation.
Science.
1984;224:1403-1406
20.
Bosch F, Jares P, Campo E, et al.
PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma.
Blood.
1994;84:2726-2732
21.
Vaandrager J, Schuuring E, Zwikstra E, et al.
Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization.
Blood.
1996;88:1177-1182 22. Kalachikov S, Migliazza A, Cayanis E, et al. Cloning and gene mapping of the chromosome 13q14 region deleted in chronic lymphocytic leukemia. Genomics. 1997;42:369-377[CrossRef][Medline] [Order article via Infotrieve].
23.
Offit K, Parsa NZ, Filippa D, Jhanwar SC, Chaganti RS.
t(9;14)(p13;q32) denotes a subset of low-grade non-Hodgkin's lymphoma with plasmacytoid differentiation.
Blood.
1992;80:2594-2599
24.
Iida S, Rao PH, Nallasivam P, et al.
The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene.
Blood.
1996;88:4110-4117
25.
Bastard C, Deweindt C, Kerckaert JP, et al.
LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients.
Blood.
1994;83:2423-2427
26.
Offit K, Lo Coco F, Louie DC, et al.
Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma.
N Engl J Med.
1994;331:74-80
27.
Lo Coco F, Ye BH, Lista F, et al.
Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma.
Blood.
1994;83:1757-1759 28. Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene. 2001;20:5595-5610[CrossRef][Medline] [Order article via Infotrieve]. 29. Cory S. Activation of cellular oncogenes in hemopoietic cells by chromosome translocation. Adv Cancer Res. 1986;47:189-234[Medline] [Order article via Infotrieve].
30.
Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM.
Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells.
Proc Natl Acad Sci U S A.
1982;79:7824-7827
31.
Taub R, Kirsch I, Morton C, et al.
Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells.
Proc Natl Acad Sci U S A.
1982;79:7837-7841 32. Seng JE, Peterson BA. Indolent B-cell non-Hodgkin's lymphomas. Oncology (Huntingt). 1987;11:1883-1894, 1901-1902.
33.
Capello D, Gaidano G.
Molecular pathophysiology of indolent lymphoma.
Haematologica.
2000;85:195-201 34. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002;2:277-288[CrossRef][Medline] [Order article via Infotrieve]. 35. Ngan BY, Chen-Levy Z, Weiss LM, Warnke RA, Cleary ML. Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. N Engl J Med. 1988;318:1638-1644[Abstract]. 36. Pezzella F, Gatter KC, Mason DY, et al. Bcl-2 protein expression in follicular lymphomas in absence of 14;18 translocation. Lancet. 1990;336:1510-1511[CrossRef][Medline] [Order article via Infotrieve]. 37. Seite P, Hillion J, d'Agay MF, et al. BCL2 gene activation and protein expression in follicular lymphoma: a report on 64 cases. Leukemia. 1993;7:410-417[Medline] [Order article via Infotrieve].
38.
Ghia P, Boussiotis VA, Schultze JL, et al.
Unbalanced expression of Bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival.
Blood.
1998;91:244-251
39.
Limpens J, Stad R, Vos C, et al.
Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals.
Blood.
1995;85:2528-2536
40.
McDonnell TJ, Nunez G, Platt FM, et al.
Deregulated Bcl-2-immunoglobulin transgene expands a resting but responsive immunoglobulin M and D-expressing B-cell population.
Mol Cell Biol.
1990;10:1901-1907 41. McDonnell TJ, Deane N, Platt FM, et al. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell. 1989;57:79-88[CrossRef][Medline] [Order article via Infotrieve]. 42. McDonnell TJ, Korsmeyer SJ. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature. 1991;349:254-256[CrossRef][Medline] [Order article via Infotrieve].
43.
Strasser A, Whittingham S, Vaux DL, et al.
Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease.
Proc Natl Acad Sci U S A.
1991;88:8661-8665
44.
Elenitoba-Johnson KS, Gascoyne RD, Lim MS, Chhanabai M, Jaffe ES, Raffeld M.
Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma.
Blood.
1998;91:4677-4685
45.
Lo Coco F, Gaidano G, Louie DC, Offit K, Chaganti RS, Dalla-Favera R.
p53 mutations are associated with histologic transformation of follicular lymphoma.
Blood.
1993;82:2289-2295
46.
Sander CA, Yano T, Clark HM, et al.
p53 mutation is associated with progression in follicular lymphomas.
Blood.
1993;82:1994-2004 47. Karsan A, Gascoyne RD, Coupland RW, Shepherd JD, Phillips GL, Horsman DE. Combination of t(14;18) and a Burkitt's type translocation in B-cell malignancies. Leuk Lymphoma. 1993;10:433-441[Medline] [Order article via Infotrieve].
48.
Yano T, Jaffe ES, Longo DL, Raffeld M.
MYC rearrangements in histologically progressed follicular lymphomas.
Blood.
1992;80:758-767
49.
Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC.
bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia.
Blood.
1993;82:1820-1828
50.
Klein U, Tu Y, Stolovitzky GA, et al.
Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells.
J Exp Med.
2001;194:1625-1638
51.
Rosenwald A, Alizadeh AA, Widhopf G, et al.
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.
J Exp Med.
2001;194:1639-1647 52. Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood. 1998;91:3379-3389. 53. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol. 2002;3:221-227[CrossRef][Medline] [Order article via Infotrieve]. 54. Beg AA, Sha WC, Bronson RT, Ghosh S, Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature. 1995;376:167-170[CrossRef][Medline] [Order article via Infotrieve].
55.
Houldsworth J, Mathew S, Rao PH, et al.
REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma.
Blood.
1996;87:25-29
56.
Rao PH, Houldsworth J, Dyomina K, et al.
Chromosomal and gene amplification in diffuse large B-cell lymphoma.
Blood.
1998;92:234-240
57.
Rosenwald A, Wright G, Chan WC, et al.
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
N Engl J Med.
2002;346:1937-1947
58.
Joos S, Otano-Joos MI, Ziegler S, et al.
Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene.
Blood.
1996;87:1571-1578
59.
Joos S, Menz CK, Wrobel G, et al.
Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2.
Blood.
2002;99:1381-1387
60.
Martin-Subero JI, Gesk S, Harder L, et al.
Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma.
Blood.
2002;99:1474-1477 61. Neri A, Chang CC, Lombardi L, et al. B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-kappa B p50. Cell. 1991;67:1075-1087[CrossRef][Medline] [Order article via Infotrieve].
62.
Migliazza A, Lombardi L, Rocchi M, et al.
Heterogeneous chromosomal aberrations generate 3' truncations of the NFKB2/lyt-10 gene in lymphoid malignancies.
Blood.
1994;84:3850-3860 63. Ohno H, Takimoto G, McKeithan TW. The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell. 1990;60:991-997[CrossRef][Medline] [Order article via Infotrieve].
64.
Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ.
Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells.
J Immunol.
2000;164:2200-2206 65. Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 1997;16:6914-6925[CrossRef][Medline] [Order article via Infotrieve]. 66. Deveraux QL, Roy N, Stennicke HR, et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998;17:2215-2223[CrossRef][Medline] [Order article via Infotrieve].
67.
Huang H, Joazeiro CA, Bonfoco E, Kamada S, Leverson JD, Hunter T.
The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7.
J Biol Chem.
2000;275:26661-26664
68.
Suzuki Y, Nakabayashi Y, Takahashi R.
Ubiquitin-protein ligase activity of X-linked inhibitor of apoptosis protein promotes proteasomal degradation of caspase-3 and enhances its anti-apoptotic effect in Fas-induced cell death.
Proc Natl Acad Sci U S A.
2001;98:8662-8667 69. Uren AG, O'Rourke K, Aravind LA, et al. Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol Cell. 2000;6:961-967[Medline] [Order article via Infotrieve]. 70. Stoffel A, Le Beau MM. The API2/MALT1 fusion product may lead to germinal center B cell lymphomas by suppression of apoptosis. Hum Hered. 2001;51:1-7[Medline] [Order article via Infotrieve].
71.
Bertin J, Guo Y, Wang L, et al.
CARD9 is a novel caspase recruitment domain-containing protein that interacts with BCL10/CLAP and activates NF-kappa B.
J Biol Chem.
2000;275:41082-41086
72.
Guiet C, Vito P.
Caspase recruitment domain (CARD)-dependent cytoplasmic filaments mediate bcl10-induced NF-kappaB activation.
J Cell Biol.
2000;148:1131-1140 73. Gaide O, Martinon F, Micheau O, Bonnet D, Thome M, Tschopp J. Carma1, a CARD-containing binding partner of Bcl10, induces Bcl10 phosphorylation and NF-kappaB activation. FEBS Lett. 2001;496:121-127[CrossRef][Medline] [Order article via Infotrieve].
74.
Lucas PC, Yonezumi M, Inohara N, et al.
Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway.
J Biol Chem.
2001;276:19012-19019
75.
Ye H, Dogan A, Karran L, et al.
BCL10 expression in normal and neoplastic lymphoid tissue: nuclear localization in MALT lymphoma.
Am J Pathol.
2000;157:1147-1154 76. Ohshima K, Muta H, Kawasaki C, et al. Bcl10 expression, rearrangement and mutation in MALT lymphoma: correlation with expression of nuclear factor-kappaB. Int J Oncol. 2001;19:283-289[Medline] [Order article via Infotrieve].
77.
Maes B, Demunter A, Peeters B, De Wolf-Peeters C.
BCL10 mutation does not represent an important pathogenic mechanism in gastric MALT-type lymphoma, and the presence of the API2-MLT fusion is associated with aberrant nuclear BCL10 expression.
Blood.
2002;99:1398-1404
78.
Landowski TH, Qu N, Buyuksal I, Painter JS, Dalton WS.
Mutations in the Fas antigen in patients with multiple myeloma.
Blood.
1997;90:4266-4270
79.
Gronbaek K, Straten PT, Ralfkiaer E, et al.
Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity.
Blood.
1998;92:3018-3024
80.
Muschen M, Re D, Brauninger A, et al.
Somatic mutations of the CD95 gene in Hodgkin and Reed-Sternberg cells.
Cancer Res.
2000;60:5640-5643 81. Seeberger H, Starostik P, Schwarz S, et al. Loss of Fas (CD95/APO-1) regulatory function is an important step in early MALT-type lymphoma development. Lab Invest. 2001;81:977-986[Medline] [Order article via Infotrieve].
82.
Takakuwa T, Dong Z, Takayama H, Matsuzuka F, Nagata S, Aozasa K.
Frequent mutations of Fas gene in thyroid lymphoma.
Cancer Res.
2001;61:1382-1385 83. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today. 1995;16:39-43[CrossRef][Medline] [Order article via Infotrieve].
84.
Straus SE, Jaffe ES, Puck JM, et al.
The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis.
Blood.
2001;98:194-200 85. Panayiotidis P, Ganeshaguru K, Foroni L, Hoffbrand AV. Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia. Leukemia. 1995;9:1227-1232[Medline] [Order article via Infotrieve]. 86. Laytragoon-Lewin N, Duhony E, Bai XF, Mellstedt H. Downregulation of the CD95 receptor and defect CD40-mediated signal transduction in B-chronic lymphocytic leukemia cells. Eur J Haematol. 1998;61:266-271[Medline] [Order article via Infotrieve]. 87. Clodi K, Snell V, Zhao S, Cabanillas F, Andreeff M, Younes A. Unbalanced expression of Fas and CD40 in mantle cell lymphoma. Br J Haematol. 1998;103:217-219[CrossRef][Medline] [Order article via Infotrieve]. 88. Lovec H, Grzeschiczek A, Kowalski MB, Moroy T. Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J. 1994;13:3487-3495[Medline] [Order article via Infotrieve].
89.
Hofmann WK, de Vos S, Tsukasaki K, et al.
Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray.
Blood.
2001;98:787-794
90.
Camacho E, Hernandez L, Hernandez S, et al.
ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances.
Blood.
2002;99:238-244
91.
Pruneri G, Fabris S, Baldini L, et al.
Immunohistochemical analysis of cyclin D1 shows deregulated expression in multiple myeloma with the t(11;14).
Am J Pathol.
2000;156:1505-1513 92. Bosch F, Campo E, Jares P, et al. Increased expression of the PRAD-1/CCND1 gene in hairy cell leukaemia. Br J Haematol. 1995;91:1025-1030[Medline] [Order article via Infotrieve].
93.
Starostik P, Manshouri T, O'Brien S, et al.
Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia.
Cancer Res.
1998;58:4552-4557
94.
Bullrich F, Rasio D, Kitada S, et al.
ATM mutations in B-cell chronic lymphocytic leukemia.
Cancer Res.
1999;59:24-27 95. Stankovic T, Weber P, Stewart G, et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet. 1999;353:26-29[CrossRef][Medline] [Order article via Infotrieve].
96.
Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, Stankovic T.
p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation.
Blood.
2001;98:814-822
97.
Wolowiec D, Ciszak L, Kosmaczewska A, et al.
Cell cycle regulatory proteins and apoptosis in B-cell chronic lymphocytic leukemia.
Haematologica.
2001;86:1296-1304
98.
el Rouby S, Thomas A, Costin D, et al.
p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression.
Blood.
1993;82:3452-3459
99.
Lin K, Sherrington PD, Dennis M, Matrai Z, Cawley JC, Pettitt AR.
Relationship between p53 dysfunction, CD38 expression, and IgVH mutation in chronic lymphocytic leukemia.
Blood.
2002;100:1404-1409
100.
Damle RN, Wasil T, Fais F, et al.
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.
Blood.
1999;94:1840-1847 101. Stuart ET, Haffner R, Oren M, Gruss P. Loss of p53 function through PAX-mediated transcriptional repression. EMBO J. 1995;14:5638-5645[Medline] [Order article via Infotrieve].
102.
Morrison AM, Jager U, Chott A, Schebesta M, Haas OA, Busslinger M.
Deregulated PAX-5 transcription from a translocated IgH promoter in marginal zone lymphoma.
Blood.
1998;92:3865-3878
103.
Baron BW, Nucifora G, McCabe N, Espinosa R III, Le Beau MM, McKeithan TW.
Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas.
Proc Natl Acad Sci U S A.
1993;90:5262-5266 104. Bajalica-Lagercrantz S, Piehl F, Lagercrantz J, et al. Expression of LAZ3/BCL6 in follicular center (FC) B cells of reactive lymph nodes and FC-derived non-Hodgkin lymphomas. Leukemia. 1997;11:594-598[CrossRef][Medline] [Order article via Infotrieve]. 105. Fukuda T, Miki T, Yoshida T, et al. The murine BCL6 gene is induced in activated lymphocytes as an immediate early gene. Oncogene. 1995;11:1657-1663[Medline] [Order article via Infotrieve].
106.
Onizuka T, Moriyama M, Yamochi T, et al.
BCL-6 gene product, a 92- to 98-kD nuclear phosphoprotein, is highly expressed in germinal center B cells and their neoplastic counterparts.
Blood.
1995;86:28-37 107. Flenghi L, Bigerna B, Fizzotti M, et al. Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region. Am J Pathol. 1996;148:1543-1555[Abstract]. 108. Dogan A, Bagdi E, Munson P, Isaacson PG. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol. 2000;24:846-852[CrossRef][Medline] [Order article via Infotrieve]. 109. Ye BH, Cattoretti G, Shen Q, et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet. 1997;16:161-170[CrossRef][Medline] [Order article via Infotrieve]. 110. Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity. 2000;13:199-212[CrossRef][Medline] [Order article via Infotrieve]. 111. Tsang P, Cesarman E, Chadburn A, Liu YF, Knowles DM. Molecular characterization of primary mediastinal B cell lymphoma. Am J Pathol. 1996;148:2017-2025[Abstract].
112.
Ueda C, Uchiyama T, Ohno H.
Immunoglobulin (Ig)/BCL6 versus non-Ig/BCL6 gene fusion in diffuse large B-cell lymphoma corresponds to a high- versus low-level expression of BCL6 mRNA.
Blood.
2002;99:2624-2625
113.
Artiga MJ, Saez AI, Romero C, et al.
A short mutational hot spot in the first intron of BCL-6 is associated with increased BCL-6 expression and with longer overall survival in large B-cell lymphomas.
Am J Pathol.
2002;160:1371-1380 114. Deweindt C, Albagli O, Bernardin F, et al. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain. Cell Growth Differ. 1995;6:1495-1503[Abstract]. 115. Baron BW, Stanger RR, Hume E, et al. BCL6 encodes a sequence-specific DNA-binding protein. Genes Chromosomes Cancer. 1995;13:221-224[Medline] [Order article via Infotrieve]. 116. Seyfert VL, Allman D, He Y, Staudt LM. Transcriptional repression by the proto-oncogene BCL-6. Oncogene. 1996;12:2331-2342[Medline] [Order article via Infotrieve].
117.
Chang CC, Ye BH, Chaganti RS, Dalla-Favera R.
BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor.
Proc Natl Acad Sci U S A.
1996;93:6947-6952 118. Turner CA Jr, Mack DH, Davis MM. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell. 1994;77:297-306[CrossRef][Medline] [Order article via Infotrieve].
119.
Lin Y, Wong K, Calame K.
Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation.
Science.
1997;276:596-599
120.
Baron BW, Anastasi J, Thirman MJ, et al.
The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: implications for a role of BCL6 in the down-regulation of apoptosis.
Proc Natl Acad Sci U S A.
2002;99:2860-2865 121. Kumagai T, Miki T, Kikuchi M, et al. The proto-oncogene Bc16 inhibits apoptotic cell death in differentiation-induced mouse myogenic cells. Oncogene. 1999;18:467-475[CrossRef][Medline] [Order article via Infotrieve]. 122. Kojima S, Hatano M, Okada S, et al. Testicular germ cell apoptosis in Bcl6-deficient mice. Development. 2001;128:57-65[Abstract].
123.
Tang TT, Dowbenko D, Jackson A, et al.
The forkhead transcription factor AFX activates apoptosis by induction of the BCL-6 transcriptional repressor.
J Biol Chem.
2002;277:14255-14265
124.
Shvarts A, Brummelkamp TR, Scheeren F, et al.
A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling.
Genes Dev.
2002;16:681-686
125.
Akasaka T, Ueda C, Kurata M, et al.
Nonimmunoglobulin (non-Ig)/BCL6 gene fusion in diffuse large B-cell lymphoma results in worse prognosis than Ig/BCL6.
Blood.
2000;96:2907-2909 126. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511[CrossRef][Medline] [Order article via Infotrieve].
127.
Huang JZ, Sanger WG, Greiner TC, et al.
The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile.
Blood.
2002;99:2285-2290
128.
Eisenman RN.
Deconstructing myc.
Genes Dev.
2001;15:2023-2030
129.
Dang CV.
c-Myc target genes involved in cell growth, apoptosis, and metabolism.
Mol Cell Biol.
1999;19:1-11 130. Amati B, Alevizopoulos K, Vlach J. Myc and the cell cycle. Front Biosci. 1998;3:D250-D268[Medline] [Order article via Infotrieve]. 131. Ayer DE, Kretzner L, Eisenman RN. Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell. 1993;72:211-222[CrossRef][Medline] [Order article via Infotrieve]. 132. Hurlin PJ, Queva C, Koskinen PJ, et al. Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation. EMBO J. 1995;14:5646-5659[Medline] [Order article via Infotrieve]. 133. Staller P, Peukert K, Kiermaier A, et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol. 2001;3:392-399[CrossRef][Medline] [Order article via Infotrieve].
134.
Coller HA, Grandori C, Tamayo P, et al.
Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion.
Proc Natl Acad Sci U S A.
2000;97:3260-3265 135. Schuldiner O, Benvenisty N. A DNA microarray screen for genes involved in c-MYC and N-MYC oncogenesis in human tumors. Oncogene. 2001;20:4984-4994[CrossRef][Medline] [Order article via Infotrieve]. 136. Yang W, Shen J, Wu M, et al. Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene. 2001;20:1688-1702[CrossRef][Medline] [Order article via Infotrieve].
137.
Wang J, Xie LY, Allan S, Beach D, Hannon GJ.
Myc activates telomerase.
Genes Dev.
1998;12:1769-1774
138.
Zindy F, Eischen CM, Randle DH, et al.
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization.
Genes Dev.
1998;12:2424-2433
139.
Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL.
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
Genes Dev.
1999;13:2658-2669
140.
Eischen CM, Woo D, Roussel MF, Cleveland JL.
Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis.
Mol Cell Biol.
2001;21:5063-5070 141. Spencer CA, Groudine M. Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res. 1991;56:1-48[Medline] [Order article via Infotrieve].
142.
Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR.
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability.
Genes Dev.
2000;14:2501-2514
143.
Kramer MH, Hermans J, Wijburg E, et al.
Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma.
Blood.
1998;92:3152-3162
144.
Ji L, Arcinas M, Boxer LM.
NF-kappa B sites function as positive regulators of expression of the translocated c-myc allele in Burkitt's lymphoma.
Mol Cell Biol.
1994;14:7967-7974
145.
Cesarman E, Dalla-Favera R, Bentley D, Groudine M.
Mutations in the first exon are associated with altered transcription of c-myc in Burkitt lymphoma.
Science.
1987;238:1272-1275 146. Pasqualucci L, Neumeister P, Goossens T, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412:341-346[CrossRef][Medline] [Order article via Infotrieve].
147.
Chang CC, Liu YC, Cleveland RP, Perkins SL.
Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas.
Am J Clin Pathol.
2000;113:512-518 148. Pagnano KB, Vassallo J, Lorand-Metze I, Costa FF, Saad ST. p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas. Am J Hematol. 2001;67:84-92[CrossRef][Medline] [Order article via Infotrieve]. 149. Hernandez L, Hernandez S, Bea S, et al. c-myc mRNA expression and genomic alterations in mantle cell lymphomas and other nodal non-Hodgkin's lymphomas. Leukemia. 1999;13:2087-2093[CrossRef][Medline] [Order article via Infotrieve].
150.
Sherr CJ.
The Pezcoller lecture: cancer cell cycles revisited.
Cancer Res.
2000;60:3689-3695 151. Martinez JC, Piris MA, Sanchez-Beato M, et al. Retinoblastoma (Rb) gene product expression in lymphomas: correlation with Ki67 growth fraction. J Pathol. 1993;169:405-412[CrossRef][Medline] [Order article via Infotrieve]. 152. Jares P, Campo E, Pinyol M, et al. Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas: correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity. Am J Pathol. 1996;148:1591-1600[Abstract].
153.
Hangaishi A, Ogawa S, Imamura N, et al.
Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and Rb genes in primary lymphoid malignancies.
Blood.
1996;87:4949-4958
154.
Ginsberg AM, Raffeld M, Cossman J.
Inactivation of the retinoblastoma gene in human lymphoid neoplasms.
Blood.
1991;77:833-840
155.
Kiviniemi M, Sauroja I, Rajamaki A, Punnonen K, Soderstrom KO, Salminen E.
Cell cycle regulators p27 and pRb in lymphomas 156. Sanchez-Beato M, Martinez-Montero JC, Doussis-Anagnostopoulou TA, et al. Anomalous retinoblastoma protein expression in Sternberg-Reed cells in Hodgkin's disease: a comparative study with p53 and Ki67 expression. Br J Cancer. 1996;74:1056-1062[Medline] [Order article via Infotrieve]. 157. Weide R, Tiemann M, Pfluger KH, et al. Altered expression of the retinoblastoma gene product in human high grade non-Hodgkin's lymphomas. Leukemia. 1994;8:97-101[Medline] [Order article via Infotrieve]. 158. Sanchez E, Chacon I, Plaza MM, et al. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol. 1998;16:1931-1939[Abstract].
159.
Morente MM, Piris MA, Abraira V, et al.
Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression.
Blood.
1997;90:2429-2436
160.
Zojer N, Konigsberg R, Ackermann J, et al.
Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization.
Blood.
2000;95:1925-1930
161.
Cinti C, Leoncini L, Nyongo A, et al.
Genetic alterations of the retinoblastoma-related gene RB2/p130 identify different pathogenetic mechanisms in and among Burkitt's lymphoma subtypes.
Am J Pathol.
2000;156:751-760
162.
Sanchez-Beato M, Camacho FI, Martinez-Montero JC, et al.
Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression: p27/KIP1-cyclin D3 colocalization in tumor cells.
Blood.
1999;94:765-772 163. Doglioni C, Chiarelli C, Macri E, et al. Cyclin D3 expression in normal, reactive and neoplastic tissues. J Pathol. 1998;185:159-166[CrossRef][Medline] [Order article via Infotrieve].
164.
Filipits M, Jaeger U, Pohl G, et al.
Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma.
Clin Cancer Res.
2002;8:729-733
165.
Sonoki T, Harder L, Horsman DE, et al.
Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies.
Blood.
2001;98:2837-2844
166.
Delmer A, Ajchenbaum-Cymbalista F, Tang R, et al.
Overexpression of cyclin D2 in chronic B-cell malignancies.
Blood.
1995;85:2870-2876
167.
Ott MM, Bartkova J, Bartek J, et al.
Cyclin D1 expression in mantle cell lymphoma is accompanied by downregulation of cyclin D3 and is not related to the proliferative activity.
Blood.
1997;90:3154-3159 168. Corcoran MM, Mould SJ, Orchard JA, et al. Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations. Oncogene. 1999;18:6271-6277[CrossRef][Medline] [Order article via Infotrieve]. 169. Otsuki T, Jaffe ES, Wellmann A, Kumar S, Condron KS, Raffeld M. Absence of p18 mutations or deletions in lymphoid malignancies. Leukemia. 1996;10:356-360[Medline] [Order article via Infotrieve]. 170. Shiohara M, Spirin K, Said JW, et al. Alterations of the cyclin-dependent kinase inhibitor p19 (INK4D) is rare in hematopoietic malignancies. Leukemia. 1996;10:1897-1900[Medline] [Order article via Infotrieve].
171.
Villuendas R, Sanchez-Beato M, Martinez JC, et al.
Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression.
Am J Pathol.
1998;153:887-897
172.
Baur AS, Shaw P, Burri N, Delacretaz F, Bosman FT, Chaubert P.
Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas.
Blood.
1999;94:1773-1781
173.
Pinyol M, Cobo F, Bea S, et al.
p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas.
Blood.
1998;91:2977-2984
174.
Pinyol M, Hernandez L, Cazorla M, et al.
Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas.
Blood.
1997;89:272-280
175.
Dreyling MH, Bullinger L, Ott G, et al.
Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma.
Cancer Res.
1997;57:4608-4614 176. Delmer A, Tang R, Senamaud-Beaufort C, Paterlini P, Brechot C, Zittoun R. Alterations of cyclin-dependent kinase 4 inhibitor (p16INK4A/MTS1) gene structure and expression in acute lymphoblastic leukemias. Leukemia. 1995;9:1240-1245[Medline] [Order article via Infotrieve].
177.
Haidar MA, Cao XB, Manshouri T, et al.
p16INK4A and p15INK4B gene deletions in primary leukemias.
Blood.
1995;86:311-315
178.
Sanchez-Beato M, Saez AI, Navas IC, et al.
Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27.
Am J Pathol.
2001;159:205-213
179.
Koduru PR, Zariwala M, Soni M, Gong JZ, Xiong Y, Broome JD.
Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin' lymphoma.
Blood.
1995;86:2900-2905 180. Moller MB, Ino Y, Gerdes AM, Skjodt K, Louis DN, Pedersen NT. Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma. Leukemia. 1999;13:453-459[CrossRef][Medline] [Order article via Infotrieve].
181.
Klangby U, Okan I, Magnusson KP, Wendland M, Lind P, Wiman KG.
p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma.
Blood.
1998;91:1680-1687 182. Garcia JF, Villuendas R, Algara P, et al. Loss of p16 protein expression associated with methylation of the p16INK4A gene is a frequent finding in Hodgkin's disease. Lab Invest. 1999;79:1453-1459[Medline] [Order article via Infotrieve].
183.
Uchida T, Watanabe T, Kinoshita T, Murate T, Saito H, Hotta T.
Mutational analysis of the CDKN2 (MTS1/p16ink4A) gene in primary B-cell lymphomas.
Blood.
1995;86:2724-2731
184.
Ogawa S, Hangaishi A, Miyawaki S, et al.
Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies.
Blood.
1995;86:1548-1556
185.
Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, Baylin SB.
Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies.
Cancer Res.
1997;57:837-841
186.
Pinyol M, Hernandez L, Martinez A, et al.
INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene.
Am J Pathol.
2000;156:1987-1996
187.
Ichikawa A, Kinoshita T, Watanabe T, et al.
Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma.
N Engl J Med.
1997;337:529-534
188.
Koduru PR, Raju K, Vadmal V, et al.
Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma.
Blood.
1997;90:4078-4091
189.
Moller MB, Gerdes AM, Skjodt K, Mortensen LS, Pedersen NT.
Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma.
Clin Cancer Res.
1999;5:1085-1091
190.
Villuendas R, Piris MA, Algara P, et al.
The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations.
Blood.
1993;82:3151-3156
191.
Wilson WH, Teruya-Feldstein J, Fest T, et al.
Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas.
Blood.
1997;89:601-609 192. Villuendas R, Pezzella F, Gatter K, et al. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations. J Pathol. 1997;181:51-61[CrossRef][Medline] [Order article via Infotrieve].
193.
Du M, Peng H, Singh N, Isaacson PG, Pan L.
The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma.
Blood.
1995;86:4587-4593
194.
Greiner TC, Moynihan MJ, Chan WC, et al.
p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis.
Blood.
1996;87:4302-4310 195. Hernandez L, Fest T, Cazorla M, et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood. 1996;87:3351-3359. 196. Konig EA, Kusser WC, Day C, et al. p53 mutations in hairy cell leukemia. Leukemia. 2000;14:706-711[CrossRef][Medline] [Order article via Infotrieve]. 197. Preudhomme C, Dervite I, Wattel E, et al. Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases. J Clin Oncol. 1995;13:812-820[Abstract].
198.
Montesinos-Rongen M, Roers A, Kuppers R, Rajewsky K, Hansmann ML.
Mutation of the p53 gene is not a typical feature of Hodgkin and Reed-Sternberg cells in Hodgkin's disease.
Blood.
1999;94:1755-1760 199. Kupper M, Joos S, von Bonin F, et al. MDM2 gene amplification and lack of p53 point mutations in Hodgkin and Reed-Sternberg cells: results from single-cell polymerase chain reaction and molecular cytogenetic studies. Br J Haematol. 2001;112:768-775[CrossRef][Medline] [Order article via Infotrieve]. 200. Chen WG, Chen YY, Kamel OW, Koo CH, Weiss LM. p53 mutations in Hodgkin's disease. Lab Invest. 1996;75:519-527[Medline] [Order article via Infotrieve]. 201. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 2001;1:233-240[CrossRef][Medline] [Order article via Infotrieve]. 202. Villuendas R, Piris MA, Orradre JL, et al. P53 protein expression in lymphomas and reactive lymphoid tissue. J Pathol. 1992;166:235-241[CrossRef][Medline] [Order article via Infotrieve].
203.
Trumper LH, Brady G, Bagg A, et al.
Single-cell analysis of Hodgkin and Reed-Sternberg cells: molecular heterogeneity of gene expression and p53 mutations.
Blood.
1993;81:3097-3115
204.
Gupta RK, Patel K, Bodmer WF, Bodmer JG.
Mutation of p53 in primary biopsy material and cell lines from Hodgkin disease.
Proc Natl Acad Sci U S A.
1993;90:2817-2821 205. Sanchez-Beato M, Piris MA, Martinez-Montero JC, et al. MDM2 and p21WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease. J Pathol. 1996;180:58-64[CrossRef][Medline] [Order article via Infotrieve]. 206. Piris MA, Pezzella F, Martinez-Montero JC, et al. p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer. 1994;69:337-341[Medline] [Order article via Infotrieve].
207.
Roman-Gomez J, Castillejo JA, Jimenez A, et al.
5' CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia.
Blood.
2002;99:2291-2296
208.
Chilosi M, Doglioni C, Menestrina F, et al.
Abnormal expression of the p53-binding protein MDM2 in Hodgkin's disease.
Blood.
1994;84:4295-4300
209.
Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M.
The human MDM-2 oncogene is overexpressed in leukemias.
Blood.
1993;82:2617-2623 210. Moller MB, Nielsen O, Pedersen NT. Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities. Mod Pathol. 1999;12:1010-1016[Medline] [Order article via Infotrieve].
211.
Watanabe T, Hotta T, Ichikawa A, et al.
The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin.
Blood.
1994;84:3158-3165 212. Zhou M, Gu L, Abshire TC, et al. Incidence and prognostic significance of MDM2 oncoprotein overexpression in relapsed childhood acute lymphoblastic leukemia. Leukemia. 2000;14:61-67[CrossRef][Medline] [Order article via Infotrieve].
213.
Momand J, Jung D, Wilczynski S, Niland J.
The MDM2 gene amplification database.
Nucleic Acids Res.
1998;26:3453-3459
214.
Sanchez-Aguilera A, Sanchez-Beato M, Garcia JF, Prieto I, Pollan M, Piris MA.
p14(ARF) nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways.
Blood.
2002;99:1411-1418
215.
Lloyd RV, Erickson LA, Jin L, et al.
p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers.
Am J Pathol.
1999;154:313-323
216.
Kawamata N, Morosetti R, Miller CW, et al.
Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies.
Cancer Res.
1995;55:2266-2269
217.
Morosetti R, Kawamata N, Gombart AF, et al.
Alterations of the p27KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma.
Blood.
1995;86:1924-1930
218.
Ponce-Castaneda MV, Lee MH, Latres E, et al.
p27Kip1: chromosomal mapping to 12p12
219.
Quintanilla-Martinez L, Thieblemont C, Fend F, et al.
Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor.
Am J Pathol.
1998;153:175-182 220. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature. 1998;396:177-180[CrossRef][Medline] [Order article via Infotrieve].
221.
Hoglund M, Johansson B, Pedersen-Bjergaard J, Marynen P, Mitelman F.
Molecular characterization of 12p abnormalities in hematologic malignancies: deletion of KIP1, rearrangement of TEL, and amplification of CCND2.
Blood.
1996;87:324-330 222. Sanchez-Beato M, Saez AI, Martinez-Montero JC, et al. Cyclin-dependent kinase inhibitor p27KIP1 in lymphoid tissue: p27KIP1 expression is inversely proportional to the proliferative index. Am J Pathol. 1997;151:151-160[Abstract]. 223. Barnouin K, Fredersdorf S, Eddaoudi A, et al. Antiproliferative function of p27kip1 is frequently inhibited in highly malignant Burkitt's lymphoma cells. Oncogene. 1999;18:6388-6397[CrossRef][Medline] [Order article via Infotrieve].
224.
Erlanson M, Portin C, Linderholm B, Lindh J, Roos G, Landberg G.
Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas: prognostic implications.
Blood.
1998;92:770-777 225. Chilosi M, Chiarle R, Lestani M, et al. Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia. Br J Haematol. 2000;111:263-271[CrossRef][Medline] [Order article via Infotrieve].
226.
Chiarle R, Budel LM, Skolnik J, et al.
Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma.
Blood.
2000;95:619-626
227.
Chiarle R, Fan Y, Piva R, et al.
S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phase.
Am J Pathol.
2002;160:1457-1466 228. Saez A, Sanchez E, Sanchez-Beato M, et al. p27KIP1 is abnormally expressed in diffuse large b-cell lymphomas and is associated with an adverse clinical outcome. Br J Cancer. 1999;80:1427-1434[CrossRef][Medline] [Order article via Infotrieve].
229.
Vrhovac R, Delmer A, Tang R, Marie JP, Zittoun R, Ajchenbaum-Cymbalista F.
Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia.
Blood.
1998;91:4694-4700 230. Gronbaek K, de Nully Brown P, Moller MB, et al. Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. Leukemia. 2000;14:1727-1735[CrossRef][Medline] [Order article via Infotrieve].   CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
, have
the ability to activate either cell survival (through IAP proteins,
components of the TNFR complex) or apoptosis. The intrinsic or
mitochondrial apoptotic pathway is controlled by BCL2 family members,
including proapoptotic BID (activated by caspase-8) or BAX, or
antiapoptotic proteins, such as BCL2, MCL1, and BCL-XL.
Activation of the mitochondrial pathway involves release of cytochrome
c from mitochondria and its association with APAF-1 and procaspase-9 to
form the apoptosome. Caspase-9 is activated within this complex. IAP
(inhibitor of apoptosis proteins) are, in turn, inhibited by second
mitochondria-derived activator of caspase (SMAC). The
extrinsic and intrinsic pathways are connected via BID and caspase-3.
Some of the receptors also exert prosurvival functions through NF-
(TGF
FL or MALT
immunophenotype in contrast
with the p53
